SAM-e
Best-in-class: SAM-e
A universal methyl donor central to neurotransmitter synthesis and joint cartilage, well-studied for both mood and osteoarthritis.
SAM-e quick facts
| Suggested dose | 400–1,200 mg daily on an empty stomach. |
| How often | daily |
| Who it's for | Mood support and joint/osteoarthritis comfort. |
Decent trial evidence in depression and separately in osteoarthritis, where the mechanism is proteoglycan synthesis. Two real cautions. It can trigger mania in bipolar disorder, which is not always diagnosed at the point someone starts it. And it consumes methyl groups, so adequate B12 and folate are needed or homocysteine rises. It is unstable and needs enteric coating; degraded product is a common reason it appears not to work.
How SAM-e actually works
S-adenosyl methionine is the universal methyl donor — it supplies the methyl group for synthesis and degradation of every monoamine neurotransmitter, for phosphatidylcholine production, and for DNA methylation. It sits at the output of the methylation cycle, downstream of folate and B12, which is why it works where those are the bottleneck.
Where to get SAM-e
Find SAM-e on iHerb →The evidence for SAM-e
Graded by what exists behind each claim.
✅ Clinically validated
- Meta-analyses support SAM-e for depression (comparable to some antidepressants) and for osteoarthritis pain (comparable to NSAIDs).
- Drives methylation of neurotransmitters and joint components.
📊 Correlative data
- Low methylation capacity tracks with mood and joint issues.
🧪 Theoretical / extrapolated benefits
- Dual mood + joint benefit is well-characterized mechanistically.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What SAM-e actually does
S-adenosylmethionine is not a botanical or a vitamin. It is a high-energy metabolite your own cells make from methionine and ATP by methionine adenosyltransferase — MAT1A in liver, MAT2A almost everywhere else — and it is the methyl donor for on the order of 200 human methyltransferases. Selling it is selling a substrate that normally never leaves the cell.
The enzymes that make this a mood product, by name. Catechol-O-methyltransferase methylates dopamine, noradrenaline and adrenaline, using SAMe as the donor. Phenylethanolamine N-methyltransferase makes adrenaline from noradrenaline the same way. Phosphatidylethanolamine N-methyltransferase spends three SAMe molecules to build one phosphatidylcholine, which is why choline status and methyl status are two ends of one budget Obeid 2023. A compound that sits upstream of every monoamine methylation step is acting on the same axis as an antidepressant, which is why the serotonergic interaction further down this page is mechanistic rather than precautionary.
The exhaust is the part that gives this product a blood test. Every methyl group donated leaves S-adenosylhomocysteine behind. SAH is a product inhibitor of most methyltransferases, so the quantity that actually determines methylation capacity is the SAM to SAH ratio, not SAMe alone. SAH hydrolase then splits SAH into adenosine and homocysteine, and homocysteine has exactly three fates: remethylation by methionine synthase, which needs vitamin B12 and 5-methyltetrahydrofolate; remethylation by betaine-homocysteine methyltransferase, which needs betaine Steenge 2003; or commitment to cysteine by cystathionine beta-synthase, which needs vitamin B6. If none of those three has the cofactor it needs, a SAMe dose raises homocysteine Clarke 2010. That is the whole reason this is one of the few products in the category with a number attached to it.
The joint claim runs on a weaker chain. SAMe contributes to sulfate and to proteoglycan synthesis in cartilage, and it has been reported to modulate chondrocyte behavior. That is a substrate argument rather than a receptor one, and the clinical evidence below reflects its weakness.
Cell, rodent, human — and where it stops
Human pharmacokinetics first, because it explains the packaging. The pharmacokinetics of SAMe have been characterized after oral and intravenous administration of its tosylate disulfate salt in a multiple-dose, open-label, parallel-group study in healthy volunteers Yang 2009. Free SAMe is chemically unstable; it is sold as a stabilized salt and enteric-coated because it degrades in gastric acid.
Human depression, the best-powered head-to-head. One hundred eighty-nine outpatients with DSM-IV major depressive disorder, mean age 45, randomized for 12 weeks to SAMe 1,600–3,200 mg/day, escitalopram 10–20 mg/day, or placebo, with dose escalation at 6 weeks for nonresponse. All three arms improved by about 5 to 6 points on the 17-item Hamilton Depression Rating Scale, p < 0.001 for each, and no arm separated from any other, p > 0.05 for all comparisons. Response rates were 36% for SAMe, 34% for escitalopram and 30% for placebo; remission 28%, 28% and 17%. Gastrointestinal side effects were the commonest on SAMe, at 19% for stomach discomfort and 20% for diarrhea Mischoulon 2014.
Human depression, as an add-on. One hundred seven treatment-non-remittent outpatients with DSM-5 major depressive disorder randomized to SAMe 800 mg/day or placebo added to their antidepressant for 8 weeks. No significant between-group difference on the Montgomery-Asberg scale, p = 0.51; response 54.3% versus 50.0%, remission 43.5% versus 38.3%. SAMe changed neither homocysteine, nor red cell folate, nor BDNF, and genotype did not moderate response. One case of serotonin-syndrome-like symptoms occurred Sarris 2018.
Human depression, as monotherapy in unmedicated patients. Forty-nine patients with mild-to-moderate MDD, 800 mg/day for 8 weeks versus placebo. MADRS fell 3.76 points further on SAMe with a medium to large effect size of 0.72, but the difference was not significant at p = 0.13 against a 53% placebo response rate; an exploratory subgroup with milder symptoms reached p = 0.045 Sarris 2020.
The Cochrane arithmetic. Eight trials, 934 adults. Versus placebo as monotherapy: standardized mean difference −0.54 (95% CI −1.54 to 0.46), p = 0.29, 142 participants, 2 studies. Versus imipramine: SMD −0.04 (−0.34 to 0.27), 619 participants, 4 studies. Versus escitalopram: mean difference 0.12 (−2.75 to 2.99), 129 participants, 1 study. Added to an SSRI: mean difference −3.90 (−6.93 to −0.87), p = 0.01, 73 participants, 1 study, graded low-quality evidence Galizia 2016. Comparative network work across nutraceuticals for depression places it in the same landscape Cheng 2025.
Human osteoarthritis. Four placebo-controlled trials, 656 patients, methodological quality and reporting quality both poor. For pain the pooled standardized mean difference was −0.17 (95% CI −0.34 to 0.01), which the reviewers translated as 0.4 cm on a 10 cm visual analog scale, with zero between-trial heterogeneity. For function, SMD 0.02 (−0.68 to 0.71). The conclusion was that the review is inconclusive and that routine use should not be advised Rutjes 2009. The comparison people quote instead is a double-blind crossover of SAMe 1,200 mg/day against celecoxib 200 mg/day in knee osteoarthritis Najm 2004.
The obstacle, stated exactly. This is the strongest evidence in this cohort and it still does not say what the shelf says. Every trial enrolled people with a formal diagnosis — major depressive disorder, or symptomatic knee or hip osteoarthritis — and the reader is usually a well adult who wants a lift. The single clearest positive result in the entire dataset, the SSRI add-on, is one study of 73 people rated low quality Galizia 2016, and the larger adjunctive trial that followed it was flatly negative Sarris 2018. The joint effect, at 0.4 cm on a 10 cm scale Rutjes 2009, is below the change most patients can perceive. And in the best-powered trial neither SAMe nor a licensed SSRI beat placebo Mischoulon 2014, which is a statement about how hard this endpoint is as much as about the compound.
SAM-e — which form, and does it matter
Two salts, and the label often does not say which weight it means. SAMe is sold as the tosylate disulfate (p-toluenesulfonate) and as the 1,4-butanedisulfonate. The published human pharmacokinetics belong to the tosylate disulfate Yang 2009. Because the salt is heavier than the SAMe ion inside it, “400 mg” can mean 400 mg of salt or 400 mg of the ion, and those are materially different doses of active. Look for a label that states the ion content; if it does not, assume the smaller number.
The enteric coating is chemistry, not marketing. SAMe is unstable and hygroscopic. It degrades in gastric acid, which is why tablets are enteric-coated, and it degrades on exposure to moisture, which is why it is blister-packed rather than bottled. A tablet from an opened blister left in a bathroom, or one that has darkened from off-white, has lost potency you cannot see. Buy blister packs, store them dry, and treat an old bottle as spent rather than weak.
Empty stomach and early, and both have reasons. Food reduces absorption, and SAMe is activating enough that an evening dose produces insomnia and anxiety often enough to be the commonest reason people abandon it Mischoulon 2014.
Compare your dose to the trial doses, not to the bottle. Depression trials used 1,600–3,200 mg/day Mischoulon 2014 and 800 mg/day Sarris 2018 Sarris 2020; the osteoarthritis comparison used 1,200 mg/day Najm 2004. The card's 400–1,200 mg puts its lower end at a quarter of the largest trial dose, and at half the dose that failed as an add-on.
What would have to be true, and how you would know it was not
1. Homocysteine, and it is the real marker in this cohort. Fasting plasma homocysteine before the first tablet and again at 8 weeks on a fixed dose. Predict no rise if your B12, folate and B6 are adequate, and a rise if they are not — because every methyl group SAMe donates leaves S-adenosylhomocysteine behind and homocysteine is what that becomes, and lowering it depends entirely on the B vitamins Clarke 2010 Steenge 2003. A rise is information about your cofactors rather than about the dose, and it is correctable.
2. Mood, on an instrument, at a fixed interval. MADRS or PHQ-9 at day 0 and day 56, same time of day, same scoring rules. Predict a fall of a few points — and predict you will not be able to distinguish it from placebo, because the trial run in exactly your situation recorded a 53% placebo response rate and a non-significant p = 0.13 in favor of the drug Sarris 2020.
3. The prediction that cuts against the product. At the doses on this label, predict nothing at all if your mood is normal and your joints do not hurt. Eight hundred milligrams a day added to an antidepressant did not beat placebo in 107 people who were still unwell Sarris 2018, and the pooled joint effect across 656 patients was four millimetres on a ten-centimetre pain scale Rutjes 2009. A well person is outside every trial that has ever been run on this molecule.
4. If the joint is the reason, score the joint. WOMAC or a 100 mm pain visual analog scale at day 0 and day 84, plus one functional test you can repeat — timed stair descent, or a sit-to-stand count. Predict a change of about 4 mm on that VAS Rutjes 2009, which is worth knowing in advance because it is smaller than day-to-day variation and will be invisible without a baseline.
What will fool you: the first week. SAMe is activating, and activation reads as improved mood on every self-report scale ever written. Score at day 0 and day 56 and ignore what happens in between.
What nobody has tested yet
Nobody has enrolled a SAMe trial by one-carbon status. The adjunctive trial measured homocysteine, red cell folate and BDNF and found they did not moderate response Sarris 2018 — but measuring a biomarker in an unselected sample is not the same as recruiting the people the mechanism predicts should respond. SAMe in depressed adults with raised homocysteine and low red cell folate is the obvious trial and it has not been done.
Nobody has replicated the SSRI add-on. The one clearly positive result in the Cochrane analysis is 73 people, graded low quality Galizia 2016, and the properly powered adjunctive trial that came afterwards was negative Sarris 2018. A single adequately powered add-on trial would settle whether this product has a place in psychiatry or not.
Nobody has compared the two salts. There is a pharmacokinetic study of the tosylate disulfate Yang 2009 and no published head-to-head against the butanedisulfonate, which is what much of the shelf sells. A crossover in twelve people with plasma SAMe curves would answer it.
Nobody has reported the SAM to SAH ratio in a supplemented human. That ratio, not SAMe concentration, is what every methyltransferase actually responds to, and it has never appeared as an outcome in a supplement trial. Every claim about “improving methylation” is currently a claim about an unmeasured quantity.
And nobody has run the osteoarthritis trial the Cochrane review asked for — an adequately sized randomized parallel-group study in knee or hip osteoarthritis. That was the closing recommendation in 2009 Rutjes 2009 and it is still outstanding.
SAM-e — its own safety story, not its category's
The bipolar switch, and it is an observed event rather than an extrapolation. Across the trials pooled by Cochrane, two reports of mania or hypomania occurred among 441 participants taking SAMe Galizia 2016, and there is a published case of probable SAMe-induced mania Abeysundera 2018. Anyone with bipolar disorder, a first-degree family history of it, or a personal history of a manic or hypomanic episode on an antidepressant should not take SAMe outside psychiatric care. This warning matters more than its incidence suggests, because bipolar II is commonly undiagnosed for years and the people in that gap are precisely the ones who reach for a mood supplement first. A sudden lift into reduced sleep need, pressured speech, unusual confidence or overspending is a reason to stop the same day and to be assessed, not a reason to celebrate that it finally worked.
Serotonergic interaction, and it is additive rather than threshold-based. One case of serotonin-syndrome-like symptoms was recorded in the adjunctive trial, where participants were taking SAMe on top of antidepressants Sarris 2018. Do not combine SAMe with an SSRI, SNRI, tricyclic, MAOI, tramadol, a triptan, linezolid, dextromethorphan or St John's Wort without medical supervision. Agitation with tremor, inducible clonus, fever, sweating and rigidity is a medical emergency and not a side effect to sit out.
Homocysteine, and this is where the product bites back. SAMe raises homocysteine unless B12, B6 and folate keep pace Clarke 2010. Anyone with a known raised homocysteine or a low B12 should correct that before starting rather than after — and a low B12 with a raised homocysteine is itself a correctable cause of low mood, which makes checking it a better first move than supplementing over it.
The ordinary dose-limiting effects. Nineteen per cent stomach discomfort and 20% diarrhea in the SAMe arm of the largest trial Mischoulon 2014; insomnia and anxiety are dose-related and are the reason for morning dosing.
Levodopa, on mechanism and labeled as such. Catechol-O-methyltransferase is a SAMe-dependent enzyme and it is the enzyme that methylates levodopa; COMT inhibitors are prescribed in Parkinson's disease precisely to stop that reaction. Increasing the methyl donor for a reaction that neurologists deliberately block is a reasoned mechanistic concern rather than a trial finding, and it is enough reason for anyone on levodopa to raise SAMe with their neurologist before starting.
Who should not take it: anyone with bipolar disorder or an undiagnosed history of elevated mood Galizia 2016 Abeysundera 2018; anyone on a serotonergic drug without supervision Sarris 2018; anyone on levodopa without asking; anyone pregnant or breastfeeding, where there is no adequate controlled data; and anyone taking it as a substitute for treatment of moderate or severe depression, which is the population where the evidence is best and the stakes are highest.
Sources read for this page
- Mischoulon D, Price LH, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry 2014 · PMID 24500245
- Galizia I, Oldani L, et al. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database of Systematic Reviews 2016 · PMID 27727432
- Sarris J, Murphy J, et al. Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: an 8-week double-blind, randomized, controlled trial. European Neuropsychopharmacology 2018 · PMID 30115553
- Sarris J, Byrne GJ, et al. S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. Psychopharmacology 2020 · PMID 31712971
- Rutjes AW, Nuesch E, et al. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database of Systematic Reviews 2009 · PMID 19821403
- Najm WI, Reinsch S, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskeletal Disorders 2004 · PMID 15102339
- Abeysundera H, Gill R. Possible SAMe-induced mania. BMJ Case Reports 2018 · PMID 29950497
- Yang J, He Y, et al. Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. Clinical Therapeutics 2009 · PMID 19302903
- Clarke R, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Archives of Internal Medicine, 2010 · PMID 20937919
- Steenge GR, et al. Betaine supplementation lowers plasma homocysteine in healthy men and women. The Journal of Nutrition, 2003 · PMID 12730412
- Obeid R, et al. Choline - a scoping review for Nordic Nutrition Recommendations 2023. Food & Nutrition Research 2023 · PMID 38187796
- Cheng YC, et al. Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis. Psychological Medicine 2025 · PMID 40314175
How you would know if it worked
SAM-e is the methyl donor itself, and every methyl group it hands over leaves S-adenosylhomocysteine behind, which is broken down to homocysteine. So the number that says whether your B12 and folate are keeping pace with the dose is homocysteine, and it is the one thing about a SAM-e trial you can actually measure. If it climbs, the cofactors are the missing piece rather than the dose.
- Homocysteine Retest: 8–12 weeks after starting B vitamins.
- Vitamin B12 Retest: 8–12 weeks after starting supplementation.
- Folate, RBC Retest: 12 weeks after supplementation.
- MTHFR, DNA Analysis Retest: Never — fixed for life.
The cheapest panel carrying Homocysteine and at least one other of these is On Metformin — the B12 Nobody Checks, at $170 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
SAM-e — safety & side effects
- Nausea, insomnia and anxiety, especially at higher doses or taken late.
- Can precipitate mania in bipolar disorder — this is well documented and is the reason to know your diagnosis before using it. Do not combine with SSRIs, SNRIs, MAOIs, triptans or tramadol without medical supervision. Serotonin syndrome is rare but it is a genuine emergency — agitation, tremor, fever, rigidity — and the risk is additive rather than threshold-based.
- Take it on an empty stomach and away from food; enteric-coated forms are better tolerated. Raises homocysteine unless B12, B6 and folate are adequate.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — SAM-e in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside SAM-e
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Homocysteine | SAM-e sits in the methylation cycle. This is the functional readout |
| Vitamin B12 | B12 and folate are required for SAM-e to work at all |
| Folate, Serum | Read with B12 — deficiency in either blunts the effect |
| Comprehensive Metabolic Panel (CMP) | Liver, where SAM-e also has genuine evidence |
The Mood, Anxiety & Low Motivation panel covers these in one order — 9 markers, $181.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
SAM-e — frequently asked questions
What is SAM-e?
A universal methyl donor central to neurotransmitter synthesis and joint cartilage, well-studied for both mood and osteoarthritis.
What is the suggested dose of SAM-e?
400–1,200 mg daily on an empty stomach. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find SAM-e dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy SAM-e?
Coach Cam sources SAM-e from vetted, top-rated brands on iHerb — use the buy link on this page.
SAM-e inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What SAM-e is used for
SAM-e appears under 1 goal in the goal router.
Related Cognitive & Mood supplements
Where this goes next
SAM-e is the substrate arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.